Luna Innovations Incorporated (NASDAQ:LUNA) today announced its
financial results for its fourth quarter and full year ended
December 31, 2007. As compared to the same quarter last year,
revenues grew by 23%, from $8.0 million to $9.9 million, gross
profit increased from $2.5 million to $3.7 million, and net loss
per share declined from $0.27 to $0.11. Kent Murphy, Chairman and
Chief Executive Officer, provided this overview of Luna�s results:
�The fourth quarter proved to be a very successful one for us.
Product and license sales increased by 64% year-over-year, which
drove our overall gross margins from 31% in the fourth quarter of
2006 to 37% in our most recent quarter. With our growing backlog of
new research opportunities and a promising pipeline of potential
products, we remain well positioned to pursue our strategy and
long-term business model of investing in the product side of our
business.� Murphy added, �Advances in our nanotechnology are
proving to be a particularly promising source of potential
products. For example, in November we announced that we had been
awarded a grant from the National Heart, Lung, and Blood Institute,
one of the National Institutes of Health, to develop a new magnetic
resonance imaging (MRI) contrast agent that could improve the
diagnosis of coronary artery disease. The results of our efforts in
this area are important because they could ultimately permit the
evaluation of plaque levels without the use of potentially harmful
ionizing radiation.� In remarking on Luna�s exclusive carbon
nanomaterial in relation to its use in MRI procedures, Murphy said,
�Our tests continue to indicate that the Trimetasphere is very
effective in keeping the gadolinium safely encapsulated, thereby
reducing the risks that the Food and Drug Administration has been
providing warnings about. The unique structure of a
Trimetasphere-based contrast agent encloses the metallic signal
molecule in such a way that it will not escape under physiological
conditions and cause harm to the patient.� Murphy further remarked,
�While there are many hurdles to overcome before any of these
Trimetasphere-based agents could be approved for marketing, we are
excited because we believe we have discovered a platform technology
that has the potential to produce many new varieties of contrast
agents, expanding the use of MRI to improve the diagnostics and the
management of diseases where MRI is not currently being used.�
Fourth Quarter Financial Highlights Total revenues for the fourth
quarter of 2007 increased 23% compared to the fourth quarter of
2006. Product and license revenues represented 37% of total
revenues in the fourth quarter of 2007, compared to 28% in the
fourth quarter of 2006. Product and license revenues grew 64% to
approximately $3.7 million in the fourth quarter of 2007, compared
to $2.2 million in the fourth quarter of 2006. Gross profit for the
fourth quarter of 2007 increased to $3.7 million, or 37% of total
revenues, from $2.5 million, or 31% of total revenues, for the
corresponding period of 2006. The improved gross profit was largely
attributed to the higher proportion of product and license sales to
total revenues. Net loss per share for the fourth quarter of 2007
was $0.11 per share, which is an improvement upon a loss per share
of $0.27 for the fourth quarter of 2006. Cash and cash equivalents
totaled $12.0 million at December 31, 2007, as compared to $12.5
million at September 30, 2007 and $17.9 million at December 31,
2006. Fourth Quarter Business Highlights Technology Development
Awarded a grant from the National Heart, Lung, and Blood Institute
to develop a new diagnostic agent that could improve the diagnosis
of coronary artery disease, a condition that causes most heart
attacks. Luna is investigating using its exclusive TRIMETASPHERE�
platform which may provide the ability to use MRI to reveal plaque
buildup in the arterial walls of the heart and possibly provide
fine structural detail of the plaque. Made significant progress in
the design of new therapeutic nanomedicines using our discoveries
of functionalized nanomaterials and their beneficial effects on
inflammatory and allergic responses in animal models. Attracted
world-class experts to Luna�s nanoWorks organization, including
Vice President of Research and Development Krishan Kumar, Ph.D., an
accomplished pharmaceutical manager and scientist with extensive
pharmaceutical industry experience, and nanoImmunology Group Leader
Chris Kepley, Ph.D., who for more than two decades has devoted his
research to studying the mechanisms of allergic disease. Made
significant progress in advancing the efficiencies of organic solar
cells by applying patented TRIMETASPHERE� carbon nanomaterial
technology, which could lead to the development of more efficient
and less expensive alternative energy solutions. The U.S.
Department of Energy�s National Renewable Energy Laboratory (NREL)
recently verified that using Luna's TRIMETASPHERE� nanomaterials
significantly increase open circuit voltage in organic solar cells
by more than 40% compared to today�s standard C60 fullerenes.
Medical Devices Initiated clinical trials for Luna�s EDAC� (Emboli
Detection and Classification) QUANTIFIER under a recently announced
agreement with Terumo Cardiovascular Systems. Instrumentation, Test
& Measurement Products Expanded the Luna Technologies
division�s offerings with two new product releases, including the
PHOENIX� 1000 laser, a tunable MEMS-based product designed to
improve the performance of fiber optic test and measurement
equipment, such as our Optical Backscatter Reflectometer platform,
while reducing the size and cost of the equipment, allowing us to
address broader markets such as handheld devices. Additionally, we
introduced our PR� 4400, an advanced precision reflectometer
offering industry-leading micrometer spatial resolution, increased
measurement range, high speed measurements, greater ease of use and
a more cost-effective price point for optical component
manufacturers. Year-End Financial Highlights For the year ended
December 31, 2007, total revenues grew $10.1 million, or 43%, to
$33.7 million, compared to $23.5 million in 2006. Technology
development revenue for 2007 increased $4.6 million, or 24%, over
2006. Product and license revenue was $10.3 million in 2007,
representing a 117% increase over 2006. Gross profit increased to
$12.3 million, or 37% of revenues, for 2007, from $7.2 million, or
31% of revenues, in 2006. Operating expenses were $20.6 million in
2007, compared to $17.2 million in 2006. The increase in
year-over-year operating expenses reflects the company�s strategy
to increase its product portfolio and product sales. The company
incurred a loss from operations of $8.3 million in 2007, versus a
loss from operations of $10.0 million for the prior year. The net
loss applicable to common stockholders for 2007 was $7.8 million,
or $0.77 per share on a diluted basis, compared to the net loss
applicable to common stockholders of $9.4 million, or $1.14 per
share on a diluted basis, for the previous year. Outlook for 2008
The company anticipates continued strong growth in both its product
and license segment and its technology development division in
2008. For 2008, the company expects total revenue to be in the
range of $40.0 million to $42.0 million, consisting of product and
license revenue of $14.0 to $15.0 million and technology
development revenue of $26.0 to $27.0 million. Also for 2008, the
company anticipates a net loss in the range of $6.5 to $7.0
million. For the first quarter of 2008, the company expects revenue
of approximately $8.8 million and a net loss of approximately $2.8
million. These expected results for the first quarter of 2008
reflect the historical seasonality in the company�s revenue,
particularly in product sales, where sales volumes each year have
historically been lower in the first half of the year and higher in
the second half of the year. Conference Call Information As
previously announced, Luna Innovations will conduct an investor
conference call at 5:00 p.m. (EST) today to discuss its financial
results, business developments and expectations for 2008. The call
can be accessed by dialing 1.866.356.4279 domestically or
1.617.597.5394 internationally prior to the start of the call. The
access code is 52924878. The conference call will also be webcast
live over the Internet. The webcast can be accessed by logging on
to the �Investor Relations� section of the Luna Innovations
website, http://www.lunainnovations.com, prior to the event. The
webcast will be archived under the �Webcasts and Presentations�
section of the Luna Innovations website for at least 30 days
following the conference call. About Luna Innovations Luna
Innovations Incorporated (www.lunainnovations.com) develops and
manufactures new-generation products for the healthcare,
telecommunications, energy and defense markets. Luna�s products are
used to measure, monitor, protect and improve critical processes in
the markets we serve. Through its disciplined commercialization
business model, Luna has become a recognized leader in
transitioning science to solutions. Luna is headquartered in
Roanoke, Virginia. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995 This press release
includes information that constitutes �forward-looking statements�
made pursuant to the safe harbor provision of the Private
Securities Litigation Reform Act of 1995, including but not limited
to: (i) the nanoWorks division�s expected development of potential
products, (ii) the TRIMETASPHERE� platform technology�s ability to
produce new varieties of contrast agents and solar cells or other
alternative energy solutions, (iii) the company�s anticipated
growth in both its product and license and technology development
divisions in 2008 and increased revenues and profitability in those
areas, (iv) the company�s plans to invest in the product side of
its business, (v) the sales potential of new products, including
the EDAC� QUANTIFIER, PHOENIX� 1000 laser and the PR� 4400, (vi)
the company�s expected backlog, (vii) the company�s ability to
continue to attract world class experts and (viii)�the company�s
financial outlook for its first quarter 2008 and full fiscal year
2008, including expected revenues and net loss. The company
attempts, whenever possible, to identify forward-looking statements
by words such as �intends,� �will,� �plans,� �anticipates,�
�expects,� �may,� �estimates,� �believes,� �should,� �projects,� or
�continue,� or the negative of those words and other comparable
words. Similarly, statements that describe the company�s business
strategy, goals, prospects, opportunities, outlook, objectives,
plans or intentions are also forward-looking statements. Actual
events or results may differ materially from the expectations
expressed in such forward-looking statements as a result of various
factors, including risks and uncertainties, many of which are
beyond the company�s control. Factors that could cause actual
results to differ materially from the expectations expressed in
such forward-looking statements include, but are not limited to:
the company�s ability to manage its growth effectively; the
company�s ability to transition its revenue mix to product revenues
and the company�s limited experience in manufacturing products on a
commercial scale; the company�s ability to successfully identify
market needs for new products; the company�s ability to attract
skilled employees; the company�s continued reliance on contract
research, including government grants and contracts available only
to small businesses, for a significant portion of its revenue; the
company�s ability to remain eligible for small business government
grants and contracts in the future; the company�s ability to
maintain sufficient proprietary rights to protect its technologies;
the potential adverse effects of nanotechnology, whether real or
perceived; and the potential limitations of regulatory requirements
in obtaining clearance by the U.S. Food and Drug Administration or
other regulatory agencies for the company�s products. Additional
factors that may affect the future results of the company are set
forth in the company�s quarterly and annual reports on Form 10-Q
and Form 10-K, respectively, and other filings with the Securities
and Exchange Commission (�SEC�), which are available at the SEC�s
website at http://www.sec.gov, and at the Company�s website at
http://www.lunainnovations.com. These risk factors are updated from
time to time through the filing of periodic reports with the SEC.
The statements made in this press release are based on information
available to the company as of the date of this release and Luna
Innovations undertakes no obligation to update any of the
forward-looking statements herein after the date of this press
release. � Luna Innovations Incorporated Consolidated Statements of
Operations � � � Three Months Ended � Twelve Months Ended December
31, December 31, 2007 � 2006 2007 � 2006 (unaudited) (unaudited)
Revenues: Technology development revenues $ 6,265,004 $ 5,810,797 $
23,356,456 $ 18,787,863 Product and license revenues � 3,671,462 �
� 2,236,376 � � 10,325,659 � � 4,757,779 � Total revenues 9,936,466
8,047,173 33,682,115 23,545,642 Cost of revenues: Contract research
costs 4,626,536 4,540,201 16,546,140 14,140,605 Product and license
costs � 1,648,822 � � 1,026,427 � � 4,819,825 � � 2,221,396 � Total
cost of revenues � 6,275,358 � � 5,566,628 � � 21,365,965 � �
16,362,001 � Gross profit 3,661,108 2,480,545 12,316,150 7,183,641
Operating expense � 4,870,622 � � 5,344,918 � � 20,570,479 � �
17,150,195 � Operating loss � (1,209,514 ) � (2,864,373 ) �
(8,254,329 ) � (9,966,554 ) Other income (expense) Other income
(expense) (18,112 ) 15,503 32,722 25,834 Interest income /
(expense), net � 76,231 � � 170,024 � � 371,991 � � 515,818 � Total
other income (expense) � 58,119 � � 185,527 � � 404,713 � � 541,652
� Loss before income taxes (1,151,395 ) (2,678,846 ) (7,849,616 )
(9,424,902 ) Income tax expense (benefit) � - � � - � � - � �
12,829 � Net loss $ (1,151,395 ) $ (2,678,846 ) $ (7,849,616 ) $
(9,437,731 ) Net loss per share: Basic $ (0.11 ) $ (0.27 ) $ (0.77
) $ (1.14 ) Diluted $ (0.11 ) $ (0.27 ) $ (0.77 ) $ (1.14 )
Weighted average shares: Basic � 10,465,501 � � 9,883,057 � �
10,219,711 � � 8,283,074 � Diluted � 10,465,501 � � 9,883,057 � �
10,219,711 � � 8,283,074 � � � Luna Innovations Incorporated
Consolidated Balance Sheets � � � December 31, � December 31, 2007
2006 Assets (unaudited) Current assets Cash and cash equivalents $
12,046,945 $ 17,866,753 Accounts receivable, net 9,716,610
7,233,406 Refundable income taxes 396,062 396,062 Inventory
1,675,239 843,294 Other current assets � 333,105 � � 503,703 �
Total current assets 24,167,961 26,843,218 Property and equipment,
net 5,859,515 5,730,094 Intangible assets, net 1,911,132 2,031,489
Deferred tax asset 600,000 600,000 Other assets � 10,270 � � 12,413
� Total assets $ 32,548,878 � $ 35,217,214 � Liabilities and
stockholders' equity Current liabilities Current portion of capital
lease obligation $ 23,885 $ 85,378 Current portion of long-term
debt obligation - 214,955 Accounts payable 3,024,973 2,757,381
Accrued liabilities 5,331,798 3,627,277 Deferred credits �
1,672,400 � � 874,676 � Total current liabilities 10,053,056
7,559,667 Long-term capital lease obligation 4,671 27,873 Long-term
debt obligation 5,000,000 5,000,000 Deferred credits and other long
term liabilities � 354,418 � � 554,418 � Total liabilities �
15,412,145 � � 13,141,958 � Stockholders' equity: Preferred stock,
par value $0.001, 5,000,000 shares authorized at December 31, 2007,
no shares issued and outstanding at December 31, 2007 - - Common
stock Common stock, par value $0.001, 100,000,000 shares authorized
at December 31, 2007 and December 31, 2006,10,704,456 shares issued
and outstanding at December 31, 2007 10,704 9,912 Additional
paid-in capital 34,496,063 31,585,762 Accumulated deficit �
(17,370,034 ) � (9,520,418 ) Total stockholders' equity �
17,136,733 � � 22,075,256 � Total liabilities and stockholders'
equity $ 32,548,878 � $ 35,217,214 � � � Luna Innovations
Incorporated Consolidated Statements of Cash Flows � � � Twelve
Months Ended December 31, 2007 � 2006 (unaudited) Cash flows used
in operating activities Net loss $ (7,849,616 ) $ (9,437,731 )
Adjustments to reconcile net loss to net cash provided by operating
activities: Depreciation and amortization 1,780,877 1,141,115
Deferred income taxes - - Share-based compensation 2,425,114
1,772,607 Change in assets and liabilities: Accounts receivable
(2,483,204 ) (2,103,495 ) Refundable income taxes - 118,735 Other
assets (659,205 ) (654,563 ) Accounts payable and accrued expenses
1,972,111 527,098 Deferred revenues � 597,724 � � (479,299 ) Net
cash used in operating activities � (4,216,199 ) � (9,115,533 )
Cash flows used in investing activities Acquisition of property and
equipment (1,375,612 ) (2,834,385 ) Intangible property costs �
(414,328 ) � (558,909 ) Net cash used in investing activities �
(1,789,940 ) � (3,393,294 ) Cash flows from financing activities
Net payments on line of credit Payments on debt obligation (214,953
) - Payments on capital lease obligations (84,695 ) (102,703 )
Proceeds from the issuance of common stock, net - 17,866,241
Proceeds from the exercise of options and warrants � 485,979 � �
97,203 � Net cash from financing activities � 186,331 � �
17,860,741 � Net change in cash (5,819,808 ) 5,351,914 Cash -
beginning of period � 17,866,753 � � 12,514,839 � Cash - end of
period $ 12,046,945 � $ 17,866,753 � Supplemental disclosure of
cash flow information Cash paid for interest $ - $ 45,341 Cash paid
for income taxes $ - $ 12,829 �
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024